← Every company
Axsome Therapeutics Inc Patents
What Axsome Therapeutics Inc has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.
AXSM on carbonthat →Filings on file
62
Granted
8
Still pending
54
Filed under
2 names
62 filings
Newest filing first. A pending application has no patent number yet, and most never get one.
| Invention | Patent |
|---|---|
| USE OF REBOXETINE TO TREAT NARCOLEPSYA61K 31/5375, A61P 25/20Filed as AXSOME THERAPEUTICS, INC.2026-06-16Herriot Tabuteau | pending |
| USE OF REBOXETINE TO TREAT NARCOLEPSYA61K 31/5375, A61P 25/20Filed as AXSOME THERAPEUTICS, INC.2026-06-15Herriot Tabuteau | pending |
| USE OF REBOXETINE TO TREAT NARCOLEPSYA61K 31/5375, A61P 25/20Filed as AXSOME THERAPEUTICS, INC.2026-06-15Herriot Tabuteau | pending |
| USE OF REBOXETINE TO TREAT NARCOLEPSYA61K 31/5375, A61P 25/20Filed as AXSOME THERAPEUTICS, INC.2026-05-21Herriot Tabuteau | pending |
| USE OF REBOXETINE TO TREAT NARCOLEPSYA61K 31/5375, A61P 25/20Filed as AXSOME THERAPEUTICS, INC.2026-04-24Herriot Tabuteau | pending |
| PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAMA61K 31/5415, A61P 9/04, A61P 25/06, A61K 9/2009, A61K 9/2027, A61K 9/2031, A61K 9/205, A61K 31/4196Filed as AXSOME THERAPEUTICS, INC.2026-04-13Herriot Tabuteau | pending |
| PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAMA61K 47/02, A61K 47/6951, A61P 25/06, A61K 9/0053, A61K 9/2009, A61K 31/4196, A61K 31/4439, A61K 31/5415, A61K 45/06, A61K 47/40, C08B 37/0012, C08B 37/0015Filed as AXSOME THERAPEUTICS, INC.2026-03-25Herriot Tabuteau | pending |
| SOLRIAMFETOL FOR USE IN A METHOD OF TREATING ATTENTION DEFICIT/HYPERACTIVITY DISORDERFiled as AXSOME THERAPEUTICS, INC.2026-03-20HERRIOT TABUTEAU | pending |
| SOLRIAMFETOL FOR USE IN A METHOD OF TREATING BINGE EATING DISORDERFiled as AXSOME THERAPEUTICS, INC.2026-03-06HERRIOT TABUTEAU | pending |
| PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAMA61K 31/5415, A61P 25/06, A61K 31/4196Filed as AXSOME THERAPEUTICS, INC.2026-02-27Herriot Tabuteau | pending |
| (S)-2-((S)-(2-ETHOXYPHENOXY)(PHENYL)METHYL)-4-NITROSOMORPHOLINEC07D 265/30, A61K 9/2009, A61K 9/2013, A61K 9/2054, A61K 9/2059, A61K 31/5375Filed as Axsome Therapeutics, Inc.2026-02-06Herriot Tabuteau | pending |
| METHODS OF IMPROVING DAILY FATIGUE IN PATIENTS WITH MYALGIC ENCEPHALOMYELITIS/CHRONIC FATIGUE SYNDROMEFiled as AXSOME THERAPEUTICS, INC.2026-02-05JOEL L. YOUNG | pending |
| PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAMA61K 9/2009, A61K 31/5415, A61K 47/6951, A61P 25/06, A61K 9/0053, A61K 9/2013, A61K 9/205, A61K 9/209, A61K 31/4196, C08B 37/0015, C08L 5/16, A61K2300/00Filed as AXSOME THERAPEUTICS, INC.2026-02-04Herriot Tabuteau | pending |
| PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAMA61K 9/2009, A61K 31/5415, A61K 47/6951, A61P 25/06, A61K 9/205, A61K 31/192, A61K 31/4196, A61K 33/00, A61K 47/02, A61K 47/40, C08B 37/0015, C08L 5/16, A61K2300/00Filed as AXSOME THERAPEUTICS, INC.2026-01-23Herriot Tabuteau | pending |
| PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAMA61K 9/2009, A61K 31/5415, A61K 47/6951, A61P 25/06, A61K 9/205, A61K 31/192, A61K 31/4196, A61K 33/00, A61K 47/02, A61K 47/40, C08B 37/0015, C08L 5/16, A61K2300/00Filed as AXSOME THERAPEUTICS, INC.2026-01-22Herriot Tabuteau | pending |
| PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAMA61K 9/2009, A61K 31/5415, A61K 47/6951, A61P 25/06, A61K 9/0053, A61K 9/2013, A61K 9/205, A61K 9/209, A61K 31/4196, C08B 37/0015, C08L 5/16, A61K2300/00Filed as AXSOME THERAPEUTICS, INC.2026-01-21Herriot Tabuteau | pending |
| PHARMACEUTICAL COMPOSITIONS COMPRISING ESREBOXETINEFiled as AXSOME THERAPEUTICS, INC.2026-01-21HERRIOT TABUTEAU | pending |
| DOSAGE FORMS CONTAINING ESREBOXETINE HAVING IMPROVED PURITYA61K 9/2054, A61K 31/5375, A61K 9/2009, A61K 9/2013, A61K 9/2059, A61K 9/28Filed as Axsome Therapeutics, Inc.2025-12-31Herriot Tabuteau | pending |
| POLYMORPH FORMS OF REBOXETINE AND ITS SALTSFiled as AXSOME THERAPEUTICS, INC.2025-12-22HERRIOT TABUTEAU | pending |
| METHODS OF ADMINISTERING SOLRIAMFETOL TO LACTATING WOMENA61K 31/27Filed as AXSOME THERAPEUTICS, INC.2025-12-18Herriot TABUTEAU | pending |
| PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAMA61K 31/5415, A61P 9/04, A61P 25/06, A61K 9/2009, A61K 9/2027, A61K 9/2031, A61K 9/205, A61K 31/4196Filed as AXSOME THERAPEUTICS, INC.2025-12-17Herriot Tabuteau | pending |
| SOLRIAMFETOL FOR THE TREATMENT OF CERTAIN NEUROLOGICAL CONDITIONSA61K 31/27, A61P 25/28Filed as AXSOME THERAPEUTICS, INC.2025-12-15Herriot TABUTEAU | pending |
| USE OF REBOXETINE TO TREAT NARCOLEPSYA61K 31/5375, A61P 25/20Filed as AXSOME THERAPEUTICS, INC.2025-12-11Herriot Tabuteau | pending |
| PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAMFiled as AXSOME THERAPEUTICS, INC.2025-12-10HERRIOT TABUTEAU | pending |
| SOLID FORMS OF ENANTIOPURE DEUTERIUM-ENRICHED BUPROPION AND METHODS OF USE THEREOFA61K 31/137, C07C 225/06, C07B2200/05, C07B2200/07, C07B2200/13, C07C 225/16Filed as AXSOME THERAPEUTICS, INC.2025-12-01Vincent Jacques | pending |
| PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAMA61K 9/0007, A61K 47/02, A61K 47/6951, A61P 1/00, A61P 25/06, A61K 9/0053, A61K 9/2009, A61K 9/2086, A61K 31/4196, A61K 31/4439, A61K 31/5415, A61K 45/06, A61K 47/40, C08B 37/0012, C08B 37/0015, A61K2300/00Filed as AXSOME THERAPEUTICS, INC.2025-11-24Herriot Tabuteau | pending |
| PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAMA61K 9/0007, A61K 47/02, A61K 47/6951, A61P 1/00, A61P 25/06, A61K 9/0053, A61K 9/2009, A61K 9/2086, A61K 31/4196, A61K 31/4439, A61K 31/5415, A61K 45/06, A61K 47/40, C08B 37/0012, C08B 37/0015, A61K2300/00Filed as AXSOME THERAPEUTICS, INC.2025-11-14Herriot Tabuteau | pending |
| PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAMA61K 9/0007, A61K 47/02, A61K 47/6951, A61P 1/00, A61P 25/06, A61K 9/0053, A61K 9/2009, A61K 9/2086, A61K 31/4196, A61K 31/4439, A61K 31/5415, A61K 45/06, A61K 47/40, C08B 37/0012, C08B 37/0015, A61K2300/00Filed as AXSOME THERAPEUTICS, INC.2025-11-14Herriot Tabuteau | pending |
| PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAMA61K 9/2009, A61K 47/02, A61K 47/6951, A61P 25/06, A61K 9/0053, A61K 9/209, A61K 31/4196, A61K 31/4439, A61K 31/5415, A61K 45/06, A61K 47/40, C08B 37/0012, C08B 37/0015, C08L 5/16Filed as AXSOME THERAPEUTICS, INC.2025-11-14Herriot Tabuteau | pending |
| PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAMFiled as AXSOME THERAPEUTICS, INC.2025-11-03Herriot Tabuteau | pending |
| PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAMA61K 31/4196, A61K 47/02, A61K 47/6951, A61P 25/06, A61K 9/0053, A61K 9/2009, A61K 9/209, A61K 31/4439, A61K 31/5415, A61K 45/06, A61K 47/40, C08B 37/0012, C08B 37/0015, C08L 5/16, A61K2300/00Filed as AXSOME THERAPEUTICS, INC.2025-10-23Herriot Tabuteau | pending |
| PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAMFiled as AXSOME THERAPEUTICS, INC.2025-10-15Herriot Tabuteau | pending |
| USE OF REBOXETINE TO TREAT NARCOLEPSYA61P 25/02, A61K 31/5375, A61P 25/20, A61P 25/00, A61K 47/12, A61K 47/36, A61K 47/38Filed as AXSOME THERAPEUTICS, INC.2025-10-15Herriot Tabuteau | pending |
| POLYMORPH FORMS OF REBOXETINE AND ITS SALTSFiled as AXSOME THERAPEUTICS, INC.2025-09-24Herriot Tabuteau | pending |
| USE OF REBOXETINE TO TREAT NARCOLEPSYFiled as AXSOME THERAPEUTICS, INC.2025-09-18KAREN TENHUISEN | pending |
| USE OF REBOXETINE TO TREAT NARCOLEPSYA61P 25/02, A61K 31/5375, A61P 25/20, A61P 25/00, A61K 47/12, A61K 47/36, A61K 47/38Filed as AXSOME THERAPEUTICS, INC.2025-09-03Herriot Tabuteau | pending |
| PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAMA61K 31/5415, A61P 9/04, A61P 25/06, A61K 9/2009, A61K 9/2027, A61K 9/2031, A61K 9/205, A61K 31/4196Filed as AXSOME THERAPEUTICS, INC.2025-08-21Herriot Tabuteau | pending |
| USE OF ESREBOXETINE TO TREAT NERVOUS SYSTEM DISORDERS SUCH AS FIBROMYALGIAA61K 31/5375, A61K 31/5377, A61P 25/24, A61K 31/137, A61K 45/06Filed as AXSOME THERAPEUTICS, INC.2025-07-23Herriot Tabuteau | pending |
| DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPIONA61K 31/485, A61K 9/0053, A61K 9/08, A61K 9/20, A61K 9/48, A61K 31/137, A61K 31/138, A61K 31/4748Filed as AXSOME THERAPEUTICS, INC.2025-07-23Herriot Tabuteau | pending |
| DOSAGE FORMS CONTAINING REBOXETINE HAVING IMPROVED PURITYFiled as Axsome Therapeutics, Inc.2025-07-22Herriot Tabuteau | pending |
| SOLRIAMFETOL FOR THE TREATMENT OF CERTAIN CNS CONDITIONSFiled as AXSOME THERAPEUTICS, INC.2025-07-21Herriot Tabuteau | pending |
| USE OF REBOXETINE TO TREAT NARCOLEPSYFiled as AXSOME THERAPEUTICS, INC.2025-07-21Herriot Tabuteau | pending |
| SOLRIAMFETOL FOR TREATING BINGE EATING DISORDERFiled as AXSOME THERAPEUTICS, INC.2025-07-21Herriot TABUTEAU | pending |
| SOLRIAMFETOL FOR TREATING BINGE EATING DISORDERFiled as AXSOME THERAPEUTICS, INC.2025-07-20Herriot Tabuteau | pending |
| SOLRIAMFETOL FOR THE TREATMENT OF CERTAIN CNS CONDITIONSFiled as AXSOME THERAPEUTICS, INC.2025-07-20Herriot Tabuteau | pending |
| USE OF REBOXETINE TO TREAT FIBROMYALGIAA61P 25/02, A61K 31/5375, A61P 25/20, A61P 25/00, A61K 47/12, A61K 47/36, A61K 47/38Filed as AXSOME THERAPEUTICS, INC.2025-07-17Herriot Tabuteau | pending |
| DOSAGE FORMS COMPRISING ACTIVE PHARMACEUTICAL INGREDIENTSA61K 9/205, A61K 9/209, A61K 47/6951, A61K 9/0053, A61K 9/2009, A61K 9/2086, A61K 31/192, A61K 31/4045, A61K 31/4184, A61K 31/4196, A61K 31/5415, C08B 37/0015, A61K2300/00Filed as AXSOME THERAPEUTICS, INC.2025-07-11Herriot Tabuteau | pending |
| PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAMA61P 25/06, A61K 31/5415, A61K 31/4196Filed as AXSOME THERAPEUTICS, INC.2025-07-08Herriot Tabuteau | 12611413 |
| PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAMA61K 9/2009, A61K 31/5415, A61K 47/6951, A61P 25/06, A61K 9/205, A61K 31/192, A61K 31/4196, A61K 33/00, A61K 47/02, A61K 47/40, C08B 37/0015, C08L 5/16, A61K2300/00Filed as AXSOME THERAPEUTICS, INC.2025-06-12Herriot Tabuteau | pending |
| PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAMFiled as AXSOME THERAPEUTICS, INC.2025-06-11Herriot Tabuteau | pending |
| PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAMA61K 9/0007, A61K 47/02, A61K 47/6951, A61P 1/00, A61P 25/06, A61K 9/0053, A61K 9/2009, A61K 9/2086, A61K 31/4196, A61K 31/4439, A61K 31/5415, A61K 45/06, A61K 47/40, C08B 37/0012, C08B 37/0015, A61K2300/00Filed as AXSOME THERAPEUTICS, INC.2025-06-06Herriot Tabuteau | 12472258 |
| PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAMA61K 9/0007, A61K 47/02, A61K 47/6951, A61P 1/00, A61P 25/06, A61K 9/0053, A61K 9/2009, A61K 9/2086, A61K 31/4196, A61K 31/4439, A61K 31/5415, A61K 45/06, A61K 47/40, C08B 37/0012, C08B 37/0015, A61K2300/00Filed as AXSOME THERAPEUTICS, INC.2025-06-05Herriot Tabuteau | 12616752 |
| PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAMA61K 9/0007, A61K 47/02, A61K 47/6951, A61P 1/00, A61P 25/06, A61K 9/0053, A61K 9/2009, A61K 9/2086, A61K 31/4196, A61K 31/4439, A61K 31/5415, A61K 45/06, A61K 47/40, C08B 37/0012, C08B 37/0015, A61K2300/00Filed as AXSOME THERAPEUTICS, INC.2025-06-04Herriot Tabuteau | 12472256 |
| PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAMA61K 9/0007, A61K 47/02, A61K 47/6951, A61P 1/00, A61P 25/06, A61K 9/0053, A61K 9/2009, A61K 9/2086, A61K 31/4196, A61K 31/4439, A61K 31/5415, A61K 45/06, A61K 47/40, C08B 37/0012, C08B 37/0015, A61K2300/00Filed as AXSOME THERAPEUTICS, INC.2025-06-04Herriot Tabuteau | 12472257 |
| PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAMA61K 9/0007, A61K 47/02, A61K 47/6951, A61P 1/00, A61P 25/06, A61K 9/0053, A61K 9/2009, A61K 9/2086, A61K 31/4196, A61K 31/4439, A61K 31/5415, A61K 45/06, A61K 47/40, C08B 37/0012, C08B 37/0015, A61K2300/00Filed as AXSOME THERAPEUTICS, INC.2025-06-04Herriot Tabuteau | 12478678 |
| TREATMENT OF NARCOLEPSY WITH REBOXETINEFiled as Axsome Therapeutics, Inc.2025-06-02Herriot Tabuteau | pending |
| METHODS AND COMPOSITIONS FOR IMPROVING DRIVING PERFORMANCEA61P 25/00, A61K 31/27, A61P 25/26, A61K 9/0053Filed as AXSOME THERAPEUTICS, INC.2025-05-30Grace WANG | pending |
| PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAMA61K 9/2009, A61K 31/5415, A61K 47/6951, A61P 25/06, A61K 9/205, A61K 31/192, A61K 31/4196, A61K 33/00, A61K 47/02, A61K 47/40, C08B 37/0015, C08L 5/16, A61K2300/00Filed as AXSOME THERAPEUTICS, INC.2025-05-29Herriot Tabuteau | 12551489 |
| TREATMENT OF NARCOLEPSY WITH REBOXETINEFiled as Axsome Therapeutics, Inc.2025-05-22Herriot Tabuteau | pending |
| PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAMA61K 9/2009, A61K 31/5415, A61K 47/6951, A61P 25/06, A61K 9/205, A61K 31/192, A61K 31/4196, A61K 33/00, A61K 47/02, A61K 47/40, C08B 37/0015, C08L 5/16, A61K2300/00Filed as AXSOME THERAPEUTICS, INC.2025-05-15Herriot Tabuteau | 12551488 |
| PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAMA61K 9/2009, A61K 31/5415, A61K 47/6951, A61P 25/06, A61K 9/205, A61K 31/192, A61K 31/4196, A61K 33/00, A61K 47/02, A61K 47/40, C08B 37/0015, C08L 5/16, A61K2300/00Filed as AXSOME THERAPEUTICS, INC.2025-05-01Herriot Tabuteau | pending |
| COMBINATION DOSAGE FORMS AND ADMINISTRATION THEREOFA61K 31/135, A61K 31/137, A61K 31/4745Filed as Axsome Therapeutics, Inc.2025-04-30Herriot TABUTEAU | pending |
Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.
More on AXSM
Company overviewEverything on AXSM in one place, with the price.SEC filingsWhat AXSM's 8-Ks say happened: results, departures, auditor changes.Insider tradingWhat AXSM's own officers and directors buy and sell.Executive payWhat AXSM awarded its chief executive, and what it became.Who owns itEvery manager reporting a position in AXSM.Funds holding itWhich funds and ETFs hold AXSM, and how big a bet.